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BACKGROUND: Intraarticular (IA) local anesthetics are often used for the management
and prevention of pain after arthroscopic knee surgery. Recently, IA tramadol was
also used for the management of these patients. However, the IA combination of
local anesthetic and tramadol has not been evaluated in arthroscopic outpatients.
Our primary aim in this study was to evaluate the analgesic effect of an IA
combination of bupivacaine and tramadol when compared with each drug alone
using visual analog scale (VAS) pain scores in patients undergoing day-care
arthroscopic knee surgery. Additionally, we assessed analgesic demand.
METHODS: Ninety ASA I/II patients undergoing arthroscopic partial meniscectomy,
performed by a single surgeon under general anesthesia, were assigned in a
randomized, double-blind manner into three groups: group B (n  30) received
0.25% bupivacaine, group T (n 30) received 100 mg tramadol, and group BT (n
30) received 0.25% bupivacaine and 100 mg tramadol to a total volume of 20 mL by
the IA route after surgery. Postoperative pain scores were measured on a VAS, at
rest and on mobilization at 0.5, 1, 2, 4, 6, 8, 12, and 24 h. Duration of analgesia, the
subsequent 24 h consumption of rescue analgesia, time to ambulation, and time to
discharge were evaluated. In addition, the systemic side effects of the IA injected
drugs were also assessed.
RESULTS: The results showed significantly lower VAS pain scores in group BT (P 
0.1) when compared with groups T and B. Group BT had a later onset of
postsurgical pain and longer time to first rescue analgesic than groups B and T. The
24 h consumption of analgesic was significantly less in group BT when compared
with the other two groups (26.7% of the patients required rescue analgesia in group
BT, whereas this number was 90% in group B and 86.7% in group T). In addition,
time in hours to discharge and time to unassisted ambulation were significantly
shorter in group BT when compared with groups T and B, and this was not
associated with any detectable systemic effects.
CONCLUSION: The IA admixture of tramadol 100 mg with bupivacaine 0.25%
provides a pronounced prolongation of analgesia compared with either drug alone
in patients undergoing day care arthroscopic knee surgery.
(Anesth Analg 2008;107:292–9)
Arthroscopic knee surgery is commonly performed
as an outpatient procedure and is often associated
with postoperative pain. Intraarticular (IA) local anes-
thetics (LA) are often used for prevention of pain after
arthroscopic knee surgery; however, the degree of
postoperative pain varies. In an effort to find the ideal
regime for sufficient, long-lasting postoperative anal-
gesia, many different drugs, including opioids, non-
steroidal antiinflammatory drugs, ketamine, clonidine,
and neostigmine, have been added to the IA LAs.1–4
The analgesic effect of IA tramadol after arthroscopic
knee surgery has been reported recently by Alagol et
al.,5 who reported that IA tramadol 100 mg without
LA provided a longer alternative analgesic effect than
after IV injection of the same dose of tramadol. How-
ever, the IA combination of LA and tramadol had not
been evaluated in outpatients undergoing arthro-
scopic knee surgery.
The primary aim of this study was to compare the
analgesic effect of IA bupivacaine 0.25% and tramadol
100 mg, used separately, and evaluate if their combi-
nation would provide superior analgesia to each drug
alone, as assessed by the Visual Analog pain Scores at
rest (VASr) and on mobilization (VASm). The second-
ary end-points were duration of analgesia, as defined
From the Departments of *Anesthesiology, †Orthopedic surgery,
Sahel General Hospital, and ‡Department of Anesthesiology,
American University of Beirut Medical Center, Beirut, Lebanon;
§Department of Anesthesia, Ghent University Hospital, Depart-
ment of Anesthesia, and ¶Heymans Institute of Pharmacology,
Ghent University, Gent, Belgium.
Accepted for publication January 22, 2008.
Address correspondence and reprint requests to Ahed Zeidan,
Department of Anesthesiology, Sahel General Hospital, Airport
Ave., P. O. BOX 99/25-Ghobeiry, Beirut, Lebanon. Address e-mail
to doczeidan@hotmail.com.
Copyright © 2008 International Anesthesia Research Society
DOI: 10.1213/ane.0b013e31816ba364
Vol. 107, No. 1, July 2008292
by first demand for analgesia (1 g of oral paracetamol),
and subsequent 24-h consumption. The time of unas-
sisted ambulation, time to discharge, and side effects
were also assessed.
METHODS
After IRB approval and informed written consents,
90 unpremedicated patients scheduled to undergo
elective arthroscopic surgery by a single surgeon were
included in this prospective, randomized, double-
blind study. Patients eligible for participation were
older than 18 yr, and were ASA physical status I or II.
Patients excluded were those treated with narcotics
preoperatively and those who had a contraindication
to the use of bupivacaine or tramadol.
Before the operation, all patients received instruc-
tions for using a 100-mm VAS score (with 0 no pain,
to 100 the worst imaginable pain). The baseline pain
scores were recorded postoperatively. Pain was as-
sessed by a single interviewer who was not aware of
the study medication. Anesthesia was induced with
propofol (2.5 mg/kg), rocuronium (0.6 mg/kg) and
fentanyl (0.002 mg/kg) and maintained with nitrous
oxide 60% in oxygen and sevoflurane. No other
supplementary analgesic medication was given dur-
ing the operation after the first dose of fentanyl.
During anesthesia, controlled ventilation was per-
formed via an endotracheal tube. Before surgical inci-
sion, a thigh pneumatic tourniquet on the same side as
the surgery, at a pressure of 300 mm Hg, was applied
to all patients. The same surgeon performed all surgi-
cal procedures using a standard surgical technique.
At the end of the operation, patients were allocated,
using a randomized number table, into 1 of 3 groups,
consisting of 30 patients each. Group T received 100
mg of IA tramadol, group B received 0.25% bupiva-
caine, and group BT received a mixture of 0.25%
bupivacaine and tramadol 100 mg. The volume of the
injectate was standardized at 20 mL. The study solu-
tion, supplied in a coded syringe, was injected by the
surgeon into the knee joint through an arthroscope at
the end of surgery, 10 min before tourniquet release.
After the end of anesthesia, patients were trans-
ferred to the postanesthesia care unit. Arrival at the
postanesthesia care unit was recorded as time zero.
The VAS was assessed at predetermined intervals
after surgery (0.5, 1, 2, 4, 6, 8, 12, and 24 h). At each
time of measurement, pain scoring was performed at
rest (VASr) and on mobilization (VASm) (bending of
the operated knee). When patients complained of pain
(VAS score more than 40), they were given 1 g of
paracetamol orally as a rescue medication. Duration
of effective analgesia was measured from the time of
surgery completion until first requirement of rescue
analgesia.
When patients were discharged, they were given a
data sheet and they were instructed how to evaluate
the degree of pain by using the VAS score ruler.
Therefore, they could read by themselves the corre-
sponding numerical score, record it on the data sheet
at the predetermined times, and report their analgesic
consumption. Also, the patients were asked to record
any adverse effect, such as headache, dizziness, som-
nolence, nausea, and vomiting.
Patients were discharged from the hospital when
they were oriented to time and place, were able to
void, had stable vital signs, and could ambulate with
or without the assistance of crutches. The time of
ambulation without any assistance (unassisted ambu-
lation) was the time considered on the data sheet.
All patients were interviewed by the anesthesiolo-
gist the day after surgery, to evaluate postoperative
pain and adverse effects. The patient-recorded data
were subsequently collected.
Statistical analysis
A power analysis considered a change of 30 mm in
the VAS score as a significant clinical difference, a
standard deviation (sd) of 35 mm was reported in
previous studies, a type I error of 5% and a type II
error of 10% yielded a sample size of at least 30
patients in each group.
The percentage of patients requiring rescue analgesia
in the three groups was compared using the Fisher’s
exact test. Statistical significance was considered at P 
0.05. The analysis of variance with post hoc Scheffe´ test
was used to compare the mean  sd of the VAS pain
scores and other continuous data among the three
groups. Additionally, to control the assumption of the
inter- and intraindividual variability across the VAS
observation and its influence on statistical decision mak-
ing, we also performed a nonparametric analysis of the
VAS scores, using nonlinear mixed effect modeling
(NONMEM). The model parameters (VAS scores versus
time) were estimated using NONMEM version VI
(Globomax LLC, Hanover, MD). For the parameters,
interindividual variability wasmodeled using a constant
coefficient of variation model,
i  TV  (1 i)
where i refers to the individual value of the param-
eter, qTV is the typical value of the parameter, and  is
a normally distributed random variable with mean
zero and a variance of 2. Individual variability is
reported as , the sd of  in the log domain, which is
approximately the coefficient of variation in the stan-
dard domain. Residual intraindividual variability was
modeled using a standard additive error model,
DVobs  DVeps  
where DVobs refers to the observed dependent vari-
able, and DVexp refers to the predicted dependent
variable,  is normally distributed with mean zero and
variance 2. The objective function for the analysis
was 2 log likelihood (2LL).
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The possible therapeutic effect of tramadol, bupiv-
acaine, or the combination of both drugs on the VAS
score was modeled as an additional effect. We first
assumed that the underlying model which describes
the relationship between the VAS versus time would
not be influenced by the drugs used. Therefore, we
first estimated the 2LL when no additional effect
was present. Thereafter, we estimated the 2LL add-
ing an additional effect on one or more of the thera-
peutic groups. This additional effect was significantly
compared with no effect if the difference in objective
function with no effect was more than P  0.05 (2
test) or 3.84 difference in the 2LL adding 1 parame-
ter for nested models. Various models were tested,
being group B  group T  group BT; group T 
group B  group BT; group B  group T  group BT;
and group B  group T  group BT. For the purpose
of the analysis, we also assumed a similar additional
effect on the VAS at all time points per group. The
control file of the final best fitting model can be found
in Appendix.
RESULTS
Demographic and surgical data are presented in
Table 1. There were no statistically significant differ-
ences among the three groups with respect to age,
weight, gender, and duration of surgery.
The recorded postoperative VASr and VASm for each
patient versus time are plotted in the upper part of
Figures 1 and 2, respectively. At all times and for both
VASr and VASm, the VAS scores were significantly
lower in group BTwhen comparedwith groups B and T,
as shown in Tables 2 and 3. The additional NONMEM
analysis showed a similar result. The best model was
found when an additional therapeutic effect was added
to group BT, however, without differentiating a separate
effect between groups B and T. This final model resulted
in a lower 2LL (difference of 39 points) and it was
compared with the model without additional effect,
which represents a large statistical significance (P 
0.01) between group BT versus groups B and T. Amodel
predicting a different effect among the three groups did
Figure 1. Patient visual analog scores (VAS) at rest: Upper part: Individual measured VAS scores versus time for the three
groups. Lower part: Individual (post hoc) predicted VAS scores as predicted by NONMEM for each group.
Table 1. Demographic and Surgical Data
Group B (n  30) Group T (n  30) Group BT (n  30)
Age (yr) 34.0 11.0 32.9 10.4 36.6 11.6
Weight (kg) 69.6 7.1 68.9 7.5 71.5 7.7
Gender (M/F) 17/13 16/14 15/15
Time of surgery (min) 40.5 7.1 39.0 7.5 41.5 6.9
B  bupivacaine; T  tramadol.
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not result in a better model fit than the final model. The
individual predicted VAS scores for each group at rest
and during mobilization are shown in Figures 1 and
2D–F. The typical values for both conditions (rest and
mobilization) at the various time points are given in
Figures 3 and 4. For both conditions, a highly significant
difference is seen between the typical values for group
BT versus groups B and T. Groups B and T have similar
typical values in the model. The interindividual variabil-
ity analysis resulted in a coefficient of variation of 18%.
The beneficial effect of the combined therapy versus
single therapy resulted in a typical VAS decrease of 14.3
with a coefficient of variation of 63%. The additive
residual intraindividual error was 15.3.
Figure 2. Patient visual analog scores (VAS) during mobilization: Upper part: Individual measured VAS scores versus time
for the three groups. Lower part: Individual (post hoc) predicted VAS scores as predicted by NONMEM for each group.
Table 2. Visual Analog Scores at Rest (VASr) as Mean  SD at Different Time Intervals Following Surgeries
Group B
(n  30)
Group T
(n  30)
Group BT
(n  30) P (B  T vs B) P (B  T vs T)
VASr–0 min 32 26 31 23 19 20 0.044 0.042
VASr–30 min 31 13 30 15 18 13 0.003 0.008
VASr–60 min 29 8 28 13 18 14 0.0001 0.005
VASr–2 h 31 14 28 12 16 14 0.0001 0.005
VASr–4 h 31 14 30 18 14 13 0.0001 0.0001
VASr–6 h 34 16 36 19 16 17 0.0001 0.0001
VASr–12 h 35 16 29 16 15 15 0.0001 0.001
VASr–24 h 30 17 29 12 12 13 0.0001 0.0001
B  bupivacaine; T  tramadol.
Table 3. Visual Analog Scores During Motion (VASm) as Mean  SD at Different Time Intervals Following Surgeries
Group B
(n  30)
Group T
(n  30)
Group BT
(n  30) P (B  T vs B) P (B  T vs T)
VASm–0 min 44 26 43  24 30  22 0.038 0.045
VASm–30 min 41 18 37  11 26  16 0.003 0.01
VASm–60 min 37 16 41  16 24  18 0.013 0.001
VASm–2 h 40 17 36  10 22  15 0.0001 0.0001
VASm–4 h 40 19 42  18 23  17 0.0001 0.0001
VASm–6 h 43 19 45  21 25  17 0.0001 0.0001
VASm–12 h 40 21 38  16 24  14 0.002 0.002
VASm–24 h 36 22 37  11 26  11 0.024 0.0001
B  bupivacaine; T  tramadol.
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Figure 3. Typical population (post
hoc) predicted visual analog scores
(VAS) for groups B and T (solid
line) and group BT (dotted line) at
rest.
Figure 4. Typical population (post
hoc) predicted visual analog scores
(VAS) for groups B and T (solid
line) and group BT (dotted line)
during mobilization.
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The percentage of patients in group BT requiring
rescue analgesia was 26.7%, which is significantly less
than the percentage of patients in either group B (90%)
or group T (86.7%). Also, the numbers of rescue
analgesia requests as well as the cumulative 24 h
analgesic consumption were significantly smaller in
group BT compared with groups B or T (Table 4).
Subsequently, time to discharge and time to unas-
sisted ambulation were significantly shorter in group
BT than in groups B or T (Table 4).
No patient, in any group, showed and/or recorded
postoperative headache, nausea, vomiting, dizziness,
or somnolence.
DISCUSSION
In the present study, we found lower VAS pain
scores, a longer duration of analgesia, and a de-
crease in the 24 h consumption of rescue analgesia
in the group receiving the IA combination of 100 mg
tramadol and 0.25% bupivacaine when compared
with the groups receiving bupivacaine or tramadol
injection alone. There was also earlier recovery of
unassisted ambulation and home discharge for the
combination group. No side effects were detected in
any groups.
Different adjuvant drugs, including opioids, nonste-
roidal antiinflammatory drugs, ketamine, clonidine, and
neostigmine, have been added to IA LAs to improve the
duration and quality of analgesia after knee arthroscopy.
A comparative study showed that the most effective
drugs administered IA are neostigmine and clonidine
when compared with tenoxicam, morphine, and bupiv-
acaine.1 Evidence indicates that a variety of these drugs
have synergistic effects through a local, rather than a
central, mechanism.
IA tramadol has also been used for pain manage-
ment of these patients.5 Alagol et al.5 showed that
tramadol 100 mg without LA provided lower VAS
pain scores and longer analgesic effect after IA admin-
istration more than after IV injection of the same doses
with no significant side effects.
In our study, IA tramadol had an analgesic effect
similar to that of IA bupivacaine. It is possible that the
combination of IA tramadol and LA provides its
regional analgesic effect by a multimodal mechanism
of action, which gives a synergistic effect, as evidenced
by the decreased VAS pain scores, decreased need for
postoperative analgesics, and an increased analgesic
duration, as well as the early unassisted ambulation
and discharge.
Although tramadol was initially considered to be a
weak 	-opioid agonist, it appears to have multimodal
mechanisms of action. It is now accepted that, in
addition to the 	-opioid agonist effect, tramadol en-
hances the function of the spinal descending inhibi-
tory pathway by inhibition of reuptake of both
5-hydroxytryptamine (5-HT) and norepinephrine, to-
gether with presynaptic stimulation of 5-HT release.6,7
The LA action of tramadol remains unproven. 5-HT3
receptors are expressed on the peripheral and spinal
terminals of the nociceptive primary afferent fibers, as
well as on the superficial lamina of the dorsal horn,
which indicates possible peripheral sites of analgesic
action for tramadol.8,9Mert et al.10 have shownadefinitive
LA effect of tramadol in experiments on frog sciatic nerves.
In their animal study, the nerve conduction block of tram-
adolwas 3–6 timesweaker than that of lidocaine.Although
lidocaine inhibits Na channels, it has been suggested that
tramadol inhibits K channels.
Although the analgesic effect of IA opioid with or
without LA after arthroscopy is controversial, the
existence of agonist-specific IA opioid receptors has
been well documented in recent years. Boden et al.11
found a significant analgesic effect of IA opioid when
injected alone and a synergistic effect when added to
the LA. It was postulated that peripheral opioid
receptors may be activated only in the presence of
tissue inflammation. The timing of IA opioid admin-
istration may also be an important factor. Whitford et
al.12 found that maintaining tourniquet inflation for 10
min after IA opioid injection improved postoperative
analgesia, presumably by allowing tissue binding be-
fore tourniquet release, and the subsequent posttour-
niquet hyperemia and tissue washout.
Furthermore, several publications reported that tra-
madol, when added to LA, modifies peripheral anes-
thesia.13,14 Kapral et al.13 reported that tramadol in-
creased the duration of analgesia when added to
mepivacaine for axillary plexus blockade.
For ethical reasons, we did not include a control
group receiving IA placebo and parenteral tramadol,
since it has been reported that tramadol provided a
Table 4. Postoperative Quality of Analgesia and Time for Discharge and Ambulation
Group B
(n  30)
Group T
(n  30)
Group BT
(n  30) P (B  T vs B) P (B  T vs T)
No. and % of patients
requiring rescue
analgesia (Paracetamol)
27 (90%) 26 (86.7%) 8 (26.7%) 0.0001 0.0001
No. of rescue analgesia 1.7 1.0 1.4 0.8 0.4  0.6 0.001 0.001
Total dose (no. of tablets/24 h) 3.3 1.9 2.7 1.6 0.8  1.3 0.001 0.001
Time to discharge (h) 7.5 2.7 7.1 2.4 5.0  1.8 0.001 0.004
Time to ambulation (h) 9.0 4.3 9.2 5.7 4.7  2.1 0.001 0.001
No.  number; %  percentage; B  bupivacaine; T  tramadol.
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longer analgesic effect after IA administration than
after IV injection of the same doses.5
Headache, nausea, vomiting, dizziness, and somno-
lence had been major side effects of IV tramadol when
used for postoperative analgesia.15 The incidence of
nausea and vomiting seems to be related mainly to the
peak serum concentrations reached by a direct IV
loading dose, which causes more symptoms than a
subsequent infusion or local infiltration.16,17 This may
partially explain the absence of side effects after the IA
tramadol administration in our patients.
In conclusion, our report showed that the IA ad-
mixture of 100 mg tramadol with 0.25% bupivacaine
decreased both VASr and VASm and provided longer
postoperative analgesia than that produced by IA
injection of either bupivacaine or tramadol alone. This
was also associated with earlier recovery of unassisted
ambulation and home discharge. Also, the IA combi-
nation of tramadol-bupivacaine was not associated
with any side effects.
APPENDIX
$PROB Intraartic_tramadol_Bupivac
$DATA DATA_REST.txt
$INPUT ID TIME POD VASDV TRT
$PRED
IF (POD.EQ.0) THEN
TYTHETA(1)*(1ETA(1))
ENDIF
IF (POD.EQ.30) THEN
TYTHETA(2)*(1ETA(1))
ENDIF
IF (POD.EQ.60) THEN
TYTHETA(3)*(1ETA(1))
ENDIF
IF (POD.EQ.120) THEN
TYTHETA(4)*(1ETA(1))
ENDIF
IF (POD.EQ.240) THEN
TYTHETA(5)*(1ETA(1))
ENDIF
IF (POD.EQ.360) THEN
TYTHETA(6)*(1ETA(1))
ENDIF
IF (POD.EQ.720) THEN
TYTHETA(7)*(1ETA(1))
ENDIF
IF (POD.EQ.1440) THEN
TYTHETA(8)*(1ETA(1))
ENDIF
IF (TRT.EQ.1) THEN
LESS0
ENDIF
IF (TRT.EQ.2) THEN
LESS0
ENDIF
IF (TRT.EQ.3) THEN
LESSTHETA(9)*(1ETA(2))
ENDIF
IPREDTY-LESS
YIPREDEPS(1)
$THETA
(0, 20, 100); Theta 01
(0, 32, 100); Theta 02
(0, 26, 100); Theta 03
(0, 23, 100); Theta 04
(0, 19, 100); Theta 05
(0, 7, 100); Theta 06
(0, 20, 100); Theta 07
(0, 20, 100); Theta 08
0.1; Theta 9
$OMEGA 0.01 0.01; Between subject variability
$SIGMA 50; Residual variability
$ESTIMATION MAX1000 PRINT1 NOABORT
METHOD1 SIG3
$TABLE ID TIME POD VAS TRT IPRED
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ERRATUM
In the article “Electrical Nerve Stimulation or Ultrasound Guidance for Lateral Sagittal Infraclavicular
Blocks: A Randomized, Controlled, Observer-Blinded, Comparative Study” which appeared in the June
2008 issue of volume 106 of Anesthesia & Analgesia on pages 1910–5, there was as a copyediting error
concerning the needle position of ultrasound guided blocks (Methods, page 1911, first column, last line).
It is stated that “the needle was placed in 9 o’clock position.” It should be “the needle was placed in
8 o’clock position.”
This error has been corrected in the online version of the article available at www.anesthesia-analgesia.org.
1. Sauter AR, Dodgson MS, Stubhaug A, Halstensen AM, Klaastad O. Electrical nerve stimulation or
ultrasound guidance for lateral sagittal infraclavicular blocks: a randomized, controlled, observer-blinded,
comparative study. Anesth Analg 2008;106:1910–5
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